On the heels of a recent upswing in anti-homeopathy activity in Australia, Canada, and the UK, the FDA recently gave surprise notice of its intent to review the legal status of homeopathic products in the U.S. marketplace. The fact that this will be the first such FDA review in twenty-five years makes its timing more than a little suspicious.
Some features are currently member only features. If you are already a member, please login. Otherwise, click here to become a member.